Clinical trials: Drug Eluting Stents
Eosinophilic Chronic Rhinosinusitis With Nasal Polyps
Efficacy and Safety of Fully Resorbable Sinus Drug-eluting Stents in Patients With Eosinophilic Chronic Rhinosinusitis With Nasal Polyps After Surgery: A Prospective, Randomized Controlled Trial
This study consists of two parts evaluating the efficacy and safety of a fully degradable sinus drug-eluting stent in patients with eosinophilic chronic rhinosinusitis with nasal polyps (ECRSwNP).
- Trial name
- NCT07498374
- Testing
- the fully degradable sinus stent, intranasal corticosteroids, oral corticosteroids
- Where
- China
- Volunteers
- 192 people
- Sponsor
- Tang-Du Hospital
Coronary Artery Disease, Coronary Disease
Dose-dependent Effect of Rosuvastatin on Long-term Clinical Outcomes After PCI
This study is a prospective, randomized, open-label, single-center trial designed to compare the 30 month-safety and efficacy between low-dose (5mg/dL) and high-dose (20mg/dL) rosuvastatin treatment for patients with coronary…
- Conditions
- Coronary Artery Disease, Coronary Disease, Cardiovascular Diseases
- Trial name
- ROSUVA-30 (NCT02859480)
- Testing
- Rosuvastatin 5mg, Rosuvastatin 20mg
- Where
- South Korea
- Volunteers
- 300 people
- Sponsor
- Korea University Anam Hospital
Coronary Stenosis, Coronary Disease
IRIS-Firehawk® Cohort in the IRIS-DES Registry
The objective of this study is to evaluate effectiveness and safety of Firehawk® stent in the "real world" daily practice as compared with other drug-eluting stents.
- Trial name
- IRIS Firehawk (NCT03380286)
- Testing
- Firehawk
- Where
- South Korea
- Sponsor
- Duk-Woo Park, MD
Ischaemic Heart Disease
BIOFREEDOM Stent Versus ORSIRO Stent: SORT OUT IX
The aim of the Danish Organization for Randomized Trials with Clinical Outcome (SORT OUT) is to compare the safety and efficacy of the polymer-free Biolimus-eluting BIOFREEDOM stent with a biodegradable-polymer Sirolimus-eluting…
- Trial name
- SORT OUT IX (NCT02623140)
- Testing
- Biofreedom, Orsiro
- Where
- Denmark
- Volunteers
- 3,150 people
- Sponsor
- Odense University Hospital
Coronary Artery Disease, Percutaneous Coronary Intervention
Comparison of Fractional FLOW Reserve Outcomes With Drug-Coated Balloon-Based Versus Drug-Eluting Stent-Only Percutaneous Coronary Intervention Strategies
The goal of this clinical trial is to find out whether a treatment strategy based on a drug-coated balloon (DCB) achieves coronary artery function at 6 months that is not worse than a strategy using only drug-eluting stents (DES)…
- Conditions
- Coronary Artery Disease, Percutaneous Coronary Intervention, Drug Coated Balloon, Drug Eluting Stents (DES)
- Trial name
- FLOW-DCB (NCT07852689)
- Testing
- Drug-coated balloon-based intervention, Drug-eluting stent-based intervention
- Where
- 4 sites in South Korea
- Volunteers
- 100 people
- Sponsor
- Korea University Guro Hospital
Unstable Angina Pectoris, Coronary Stent Implantation
Efficacy and Safety of Low Dose Ticagrelor in Patients With Unstable Angina Pectoris After Coronary Stent Implantation
The study is to evaluate efficacy and safety of low dose of ticagrelor therapy for Chinese unstable angina patients treated with non-urgent coronary stent implantation, to examine whether lower dose ticagrelor (45 mg twice-daily)…
- Trial name
- NCT03620760
- Testing
- Ticagrelor 90 mg, Ticagrelor 45 mg, Aspirin
- Where
- China
- Volunteers
- 2,036 people
- Sponsor
- Xiaofan Wu
Atherosclerosis
Optical Coherence TomOgraphy Assessment of the Drug-Eluting Stent
BACKGROUND Treatment of coronary atherosclerotic disease has been significantly advanced by interventional cardiology, and the advent of coronary arterial stents.
- Trial name
- OCTOBER (NCT01012583)
- Volunteers
- 1 people
- Sponsor
- Chinese PLA General Hospital
Coronary Artery Disease, Atherosclerosis
MASCOT - Post Marketing Registry
To collect post marketing surveillance data on patients receiving at least one Combo Bio-Engineered Sirolimus Eluting Stent when used according to the Instructions for Use.
- Trial name
- MASCOT (NCT02183454)
- Testing
- OrbusNeich COMBO stent
- Where
- Netherlands
- Volunteers
- 2,500 people
- Sponsor
- OrbusNeich
Coronary Stenosis
Randomized Trial Evaluating Slow-Release Formulation TAXUS Paclitaxel-Eluting Coronary Stents to Treat De Novo Coronary Lesions
The primary objective of this study is to further evaluate the safety and effectiveness of the TAXUS Express2 Paclitaxel-Eluting Coronary Stent System in long lesion lengths, small and large vessel diameters and with multiple…
- Trial name
- NCT00301522
- Testing
- TAXUS Paclitaxel-Eluting Coronary Stent, Slow-Formulation, Express2
- Where
- 72 sites in United States
- Volunteers
- 1,108 people
- Sponsor
- Boston Scientific Corporation
Coronary Disease
A Randomized, Multi-Center Study of the Pimecrolimus-Eluting and Pimecrolimus/Paclitaxel-Eluting Coronary Stent Systems (GENESIS)
To demonstrate non-inferiority in 6-month angiographic in-stent late lumen loss of the pimecrolimus-eluting coronary stent (Corio) compared to the CoStar coronary stent control arm and the dual pimecrolimus/paclitaxel-eluting…
- Trial name
- NCT00322569
- Testing
- Corio™ Pimecrolimus-Eluting Coronary Stent System, SymBio™ Pimecrolimus/Paclitaxel-Eluting Coronary Stent System, Costar ™ Paclitaxel-Eluting Coronary Stent System
- Where
- United Kingdom
- Volunteers
- 246 people
- Sponsor
- Cordis US Corp.
Coronary In-stent Restenosis
Restenosis Intrastent: Bioresorbable Vascular Scaffolds Treatment With Scoring Balloon Pre-dilatation (RIBS VI Scoring)
Treatment of patients with in-stent restenosis (ISR) remains a challenge. This study will assess the efficacy of Bioresorbable Vascular Scaffolds (BVS) (Abbott Vascular) in the treatment of patients suffering from ISR after…
- Trial name
- NCT03069066
- Testing
- Bioresorbable vascular scaffold. Absorb GT1 (Abbott)
- Where
- 10 sites in Spain
- Volunteers
- 100 people
- Sponsor
- Spanish Society of Cardiology
Coronary Artery Disease, Myocardial Ischemia
Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease
Prospective, randomised, open-label, international multicenter trial to evaluate the safety and efficacy of drug-coated balloon (DCB) treatment compared to drug-eluting stenting (DES) in patients with large coronary artery…
- Conditions
- Coronary Artery Disease, Myocardial Ischemia, Acute Coronary Syndrome, Coronary Stenosis
- Trial name
- REVERSE (NCT05846893)
- Testing
- SeQuent® Please NEO drug-coated balloon catheter, Current-generation drug-eluting stent
- Where
- 21 sites in Malaysia, Singapore and 2 more
- Volunteers
- 1,436 people
- Sponsor
- B. Braun Medical Industries Sdn. Bhd.
Coronary Stenosis
FrActional Flow Reserve Guided Drug Coated Balloon Only Strategy in De Novo coronarY Lesions (FADDY)
Drug-eluting stent (DES) has been the primary choice for in suit coronary lesions treatment. In comparison to bare-metal stent (BMS), it evidently decreases the rate of restenosis.
- Trial name
- FADDY (NCT03452904)
- Testing
- Drug-coated balloon, Drug-eluting stent
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Percutaneous Coronary Angioplasty
Angiographic and IVUS Follow-up After Simultaneously Implanted Different Drug-eluting Stents in Same Individuals (AIFSIDDES)
The safety and efficacy of drug-eluting stents (DES) with a biocompatible polymer have been demonstrated in randomized clinical trials as well as in real world practice.
- Trial name
- NCT01382043
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Liuhuaqiao Hospital
Coronary Artery Disease, Coronary Stenosis
SEA-SIDE: Sirolimus Versus Everolimus-eluting Stent Randomized Assessment in Bifurcated Lesions and Clinical SIgnificance of Residual siDE-branch Stenosis
BACKGROUND: Bifurcated lesions are a challenging subset in percutaneous coronary interventions (PCI). The selection of the type of DES and the technique for stent implantation have not been clarified.
- Trial name
- SEA-SIDE (NCT00697372)
- Testing
- Sirolimus eluting stent, Everolimus eluting stent
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- Catholic University of the Sacred Heart
Drug Eluting Stent
Angiographic and Intravascular Ultrasound (IVUS) Follow-up After Simultaneously Implanted Different Drug-eluting Stents in Same Individuals
The purpose of this study is to investigate if there is any different follow-up results by angiography and IVUS between two different drug-eluting stents after implanted simultaneously in same individuals.
- Trial name
- AIFSIDDES (NCT00973375)
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Liuhuaqiao Hospital
Coronary Disease, Coronary Artery Disease
ABSORB Clinical Investigation, Cohort B
The purpose of this study is to assess the safety and performance of the BVS Everolimus Eluting Coronary Stent System (EECSS) in the treatment of patients with a maximum of two de novo native coronary artery lesions located in…
- Conditions
- Coronary Disease, Coronary Artery Disease, Coronary Restenosis
- Trial name
- ABSORB B (NCT00856856)
- Testing
- Bioabsorbable Everolimus Eluting Coronary Stent
- Where
- 12 sites in Australia, Belgium and 6 more
- Volunteers
- 101 people
- Sponsor
- Abbott Medical Devices
Coronary Artery Disease
Nordic Bifurcation Stent Technique Study (BIF II)
This is a study of crush- or culotte stenting of bifurcation lesions using drug eluting stents. This is a randomized Nordic multicenter study including 400 patients with angina pectoris with clinical angiographic follow-up.
- Trial name
- BIF II (NCT00292305)
- Testing
- Percutaneous coronary intervention
- Where
- Denmark
- Volunteers
- 425 people
- Sponsor
- Aarhus University Hospital Skejby
Coronary Artery Disease, Myocardial Ischemia
Safety and Efficacy Study of the Amaranth Medical MAGNITUDE Bioresorbable Drug-Eluting Coronary Stent (RENASCENT III)
The purpose of this study is to evaluate the safety and performance of a new version of a coronary artery stent for treating blockages in the arteries supplying blood to the heart muscle.
- Trial name
- RENASCENT III (NCT02900937)
- Testing
- AmM MAGNITUDE Bioresorbable Drug-Eluting Coronary Scaffold
- Where
- 13 sites in Colombia, Italy
- Volunteers
- 70 people
- Sponsor
- Amaranth Medical Inc.
Unprotected Left Main Coronary Artery Disease
Comparison of HYBRID Versus Two-Stent Strategies in Unprotected True Left MAIN Bifurcation
The number of deaths from heart disease is rising globally, particularly in developing countries. This condition involves the narrowing of arteries that supply blood to the heart.
- Trial name
- HYBRID MAIN (NCT07159737)
- Testing
- Two-stent strategy, Hybrid Strategy
- Volunteers
- 800 people
- Sponsor
- Hospital Sultanah Bahiyah